HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co-Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician’s Offices & Clinics) & Region - Global Forecast to 2027
Market Growth Outlook Summary
The global HPV testing and Pap test market growth forecasted to transform from $4.9 billion in 2022 to $9.2 billion by 2027, driven by a CAGR of 13.2%. Market growth is driven by the increased focus of government on cervical cancer and increasing initiatives to spread the awareness on cervical cancer prevention.
To know about the assumptions considered for the study, Request for Free Sample Report
HPV Testing and Pap Test Market Dynamics
Driver: Increasing number of HPV cases and growing aging population
Increased in number of HPV cases worldwide which leads to cervical cancer which is the most common cancer. The disease is mainly attributed to genital infection. Also due to the increased in the aging population specifically women which are prone to infections. These factors will drive the market growth.
Opportunity: Introduction of HPV primary screening tests
Increased focus on introduction of different tests for the early screening of cervical cancer namely primary HPV testing is expected to offer significant growth opportunities. The diagnostic segment in the emerging market invest heavily in the development of new tests.
Restraint: Changes in regulatory guidelines for cervical cancer screening
There is significant changes in the guidelines for the screening of cervical cancer worldwide will restraint the growth of this market. These devices guidelines are revised timely and are specifically differs region wise.
Challenge: Uncertain reimbursement scenario
Reimbursement of diagnostic tests is mandated by the Affordable Care Act. High price of HPV test restricts women with lower income take this test for primary screening. If a women tests positive for Pap test it is recommended to take the primary test. This screening is provided without co-pay, co-insurance, or deductible only till she visits a doctor who accepts the payment terms of the Medicare. Which is a major challenge in the growth of this market.
HPV testing segment accounted for the largest share of the HPV testing and Pap test industry, by test type
The HPV testing segment accounted for the largest share of HPV testing and Pap test market, mainly due to the rising investment for development of new cervical diagnostic products.
HPV testing segment accounted for the largest share of the HPV testing and Pap test industry, by application
The HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. The cervical cancer screening segment accounted for the largest share of this market, mainly due to the rising increased initiatives by women for cervical cancer screening.
Hospitals segment accounted for the largest share of the HPV testing and Pap test industry, by end user
The HPV testing and Pap test market is segmented into laboratories, hospitals and physician’s offices & clinics based on end user. The hospitals segment accounted for the largest share. Factors such as increased need of cervical cancer screening to market growth.
North America is the largest regional market for HPV testing and Pap test industry
The HPV testing and Pap test market is segmented into five major regions - North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of this market. The North American market's growth can be attributed to the increase in infectious diseases like HPV infections.
To know about the assumptions considered for the study, download the pdf brochure
The major players operating in HPV Testing and Pap Test Market are Abbott Laboratories (US), Roche Diagnostics (Switzerland), Becton, Dickinson and Company (US), Hologic, Inc. (US), Quest Diagnostics (US), Qiagen N.V. (Netherland), Seegene, Inc. (US), Femasys, Inc. (US), Arbor Vita Corporation (US) and Mylab Discovery Solutions Pvt. Ltd. (India).
Scope of the HPV Testing and Pap Test Industry:
|
Report Metric |
Details |
|
Market Revenue Size in 2022 |
$4.9 billion |
|
Projected Revenue Size by 2027 |
$9.2 billion |
|
Industry Growth Rate |
Poised to grow at a CAGR of 13.2% |
|
Growth Drivers |
Increasing number of HPV cases and growing aging population |
|
Growth Opportunities |
Introduction of HPV primary screening tests |
This study categorizes the global HPV Testing and Pap Test Market to forecast revenue and analyze trends in each of the following submarkets:
By Test Type
- HPV Testing
- Pap Test
By Application
- Cervical Cancer Screening
- Vaginal Cancer Screening
By End User
- Hospitals
- Laboratories
- Physician’s Offices & Clinics
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the HPV testing and pap test market?
The HPV testing and pap test market boasts a total revenue value of $9.2 billion by 2027.
What is the estimated growth rate (CAGR) of the HPV testing and pap test market?
The global HPV testing and pap test market has an estimated compound annual growth rate (CAGR) of 13.2% and a revenue size in the region of $4.9 billion in 2022.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 30)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKETS COVERED
FIGURE 1 HPV TESTING MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 34)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 HPV TESTING MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 CAGR projections
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 7 HPV TESTING MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
2.8.1 HPV TESTING MARKET: RISK ASSESSMENT
3 EXECUTIVE SUMMARY (Page No. - 45)
FIGURE 9 HPV TESTING MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 HPV TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 11 HPV TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 12 HPV TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 48)
4.1 HPV TESTING MARKET OVERVIEW
FIGURE 13 RISING CASES OF HPV AND INCREASING R&D INITIATIVES ON CERVICAL CANCER SCREENING TO DRIVE MARKET
4.2 HPV TESTING MARKET SHARE, BY TEST TYPE, 2022 VS. 2027
FIGURE 14 HPV TESTING SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
4.3 HPV TESTING MARKET SHARE, BY APPLICATION, 2022 VS. 2027
FIGURE 15 CERVICAL CANCER SCREENING SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 HPV TESTING MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 16 HOSPITALS TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
4.5 HPV TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 51)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 HPV TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising HPV cases and subsequent increase in cervical cancer
5.2.1.2 Growing awareness of cervical cancer screening programs
5.2.1.3 Increasing R&D funding initiatives on cervical cancer prevention
5.2.2 RESTRAINTS
5.2.2.1 Growing awareness of HPV vaccination
5.2.3 OPPORTUNITIES
5.2.3.1 Regulatory guidelines for cervical cancer screening
5.2.3.2 Innovative improvements in HPV tests
5.2.3.2.1 Introduction of HPV primary screening tests
5.2.3.2.2 Technological improvements in HPV tests
5.2.4 CHALLENGES
5.2.4.1 Uncertain reimbursement scenario
5.2.4.2 Stringent regulatory & legal requirements
5.2.4.3 Operational barriers
5.3 PRICING ANALYSIS
TABLE 1 PRICE OF HPV TESTING AND PAP TEST PRODUCTS (2021)
5.4 PATENT ANALYSIS
FIGURE 19 PATENT ANALYSIS OF PAP TEST MARKET
5.5 VALUE CHAIN ANALYSIS
FIGURE 20 VALUE CHAIN ANALYSIS OF PAP TEST MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 21 PAP TEST MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP
FIGURE 22 PAP TEST MARKET: ECOSYSTEM/MARKET MAP
5.7.1 PAP TEST MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 HPV TEST MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 TRADE ANALYSIS
5.9.1 TRADE ANALYSIS FOR DIAGNOSTIC OR LABORATORY REAGENTS
TABLE 3 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 4 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.10.1 REVENUE SOURCES SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19
FIGURE 23 REVENUE SHIFT IN HPV TEST MARKET
6 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE (Page No. - 65)
6.1 INTRODUCTION
TABLE 5 HPV TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 6 HPV TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 7 HPV TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 8 HPV TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
6.2 HPV TESTING
TABLE 9 HPV TESTING MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 10 HPV TESTING MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 11 HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 12 HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)
6.2.1 FOLLOW-UP HPV TESTING
6.2.1.1 Irregular Pap test results to drive adoption
TABLE 13 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 14 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)
6.2.2 CO-TESTING
6.2.2.1 Co-testing to drive rapid detection results for cervical cancer
TABLE 15 HPV CO-TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 16 HPV CO-TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)
6.2.3 PRIMARY HPV TESTING
6.2.3.1 Test sensitivity and accuracy to drive segment growth
TABLE 17 PRIMARY HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 18 PRIMARY HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)
6.3 PAP TEST
6.3.1 RISING CASES OF FALSE-NEGATIVE TESTS TO RESTRAIN MARKET
TABLE 19 PAP TEST MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 20 PAP TEST MARKET, BY REGION, 2021–2027 (USD MILLION)
7 HPV TESTING AND PAP TEST MARKET, BY APPLICATION (Page No. - 74)
7.1 INTRODUCTION
TABLE 21 MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 22 MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
7.2 CERVICAL CANCER SCREENING
7.2.1 RISING INCIDENCE OF CERVICAL CANCER TO DRIVE MARKET
TABLE 23 MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2017–2020 (USD MILLION)
TABLE 24 MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2021–2027 (USD MILLION)
7.3 VAGINAL CANCER SCREENING
7.3.1 LIMITED SCREENING TESTS TO RESTRAIN MARKET
TABLE 25 MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2017–2020 (USD MILLION)
TABLE 26 MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2021–2027 (USD MILLION)
8 HPV TESTING AND PAP TEST MARKET, BY END USER (Page No. - 78)
8.1 INTRODUCTION
TABLE 27 HPV TEST AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 28 HPV TEST AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)
8.2 HOSPITALS
8.2.1 ADVANCED TECHNOLOGIES AND EQUIPPED FACILITIES TO DRIVE MARKET
TABLE 29 HPV TEST AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2017–2020 (USD MILLION)
TABLE 30 HPV TEST AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2021–2027 (USD MILLION)
8.3 LABORATORIES
8.3.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO LABORATORIES TO DRIVE MARKET
TABLE 31 HPV TEST AND PAP TEST MARKET FOR LABORATORIES, BY REGION, 2017–2020 (USD MILLION)
TABLE 32 HPV TEST AND PAP TEST MARKET FOR LABORATORIES, BY REGION, 2021–2027 (USD MILLION)
8.4 PHYSICIANS’ OFFICES AND CLINICS
8.4.1 RAPID AND EFFICIENT RESULTS TO SUPPORT MARKET GROWTH
TABLE 33 HPV TEST AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES AND CLINICS, BY REGION, 2017–2020 (USD MILLION)
TABLE 34 HPV TEST AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES AND CLINICS, BY REGION, 2021–2027 (USD MILLION)
9 HPV TESTING AND PAP TEST MARKET, BY REGION (Page No. - 84)
9.1 INTRODUCTION
TABLE 35 GLOBAL MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 36 GLOBAL MARKET, BY REGION, 2021–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 24 NORTH AMERICA: MARKET SNAPSHOT
TABLE 37 NORTH AMERICA: MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 38 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 40 NORTH AMERICA: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 41 NORTH AMERICA: MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 42 NORTH AMERICA: MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 43 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 44 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 46 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 48 NORTH AMERICA: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.2.1 US
9.2.1.1 Rising government initiatives for cancer research to drive market
TABLE 49 US: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 50 US: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 51 US: MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 52 US: MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 53 US: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 54 US: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 55 US: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 56 US: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 57 US: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 58 US: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Government support in raising awareness on cervical cancer screening to support market growth
TABLE 59 CANADA: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 60 CANADA: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 61 CANADA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 62 CANADA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 63 CANADA: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 64 CANADA: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 65 CANADA: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 66 CANADA: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3 EUROPE
TABLE 67 EUROPE: MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 68 EUROPE: MARKET, BY COUNTRY, 2021–2027 (USD MILLION)
TABLE 69 EUROPE: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 70 EUROPE: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 71 EUROPE: MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 72 EUROPE: MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 73 EUROPE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 74 EUROPE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 75 EUROPE: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 76 EUROPE: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 77 EUROPE: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 78 EUROPE: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Established healthcare infrastructure and rising government spending on cancer screening to drive market
TABLE 79 GERMANY: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 80 GERMANY: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 81 GERMANY: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 82 GERMANY: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 83 GERMANY: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 84 GERMANY: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 85 GERMANY: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 86 GERMANY: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.2 UK
9.3.2.1 Rising focus on research projects for specific cancers to drive market
TABLE 87 UK: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 88 UK: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 89 UK: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 90 UK: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 91 UK: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 92 UK: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 93 UK: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 94 UK: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 High incidence of cervical cancer and associated investments in genomics to support market growth
TABLE 95 FRANCE: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 96 FRANCE: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 97 FRANCE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 98 FRANCE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 99 FRANCE: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 100 FRANCE: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 101 FRANCE: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 102 FRANCE: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.4 SPAIN
9.3.4.1 Increasing research on cancer diagnostics to support market growth
TABLE 103 SPAIN: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 104 SPAIN: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 105 SPAIN: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 106 SPAIN: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 107 SPAIN: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 108 SPAIN: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 109 SPAIN: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 110 SPAIN: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.5 ITALY
9.3.5.1 Growing acceptance of molecular-based diagnostic tests for cervical cancer screening to drive market
TABLE 111 ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 112 ITALY: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 113 ITALY: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 114 ITALY: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 115 ITALY: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 116 ITALY: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 117 ITALY: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 118 ITALY: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 119 REST OF EUROPE: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 120 REST OF EUROPE: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 121 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 122 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 123 REST OF EUROPE: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 124 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 125 REST OF EUROPE: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 126 REST OF EUROPE: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 25 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 127 ASIA PACIFIC: MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 128 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2027 (USD MILLION)
TABLE 129 ASIA PACIFIC: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 130 ASIA PACIFIC: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 131 ASIA PACIFIC: MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 132 ASIA PACIFIC: MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 133 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 134 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 135 ASIA PACIFIC: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 136 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 137 ASIA PACIFIC: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 138 ASIA PACIFIC: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 Government initiatives for cancer diagnosis and immunotherapy to support market growth
TABLE 139 CHINA: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 140 CHINA: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 141 CHINA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 142 CHINA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 143 CHINA: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 144 CHINA: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 145 CHINA: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 146 CHINA: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Rising demand for technologically advanced cervical cancer screening tests to drive market
TABLE 147 JAPAN: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 148 JAPAN: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 149 JAPAN: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 150 JAPAN: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 151 JAPAN: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 152 JAPAN: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 153 JAPAN: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 154 JAPAN: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 High cancer burden and rising pharmaceutical industry to drive market
TABLE 155 INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 156 INDIA: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 157 INDIA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 158 INDIA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 159 INDIA: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 160 INDIA: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 161 INDIA: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 162 INDIA: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 163 REST OF ASIA PACIFIC: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 164 REST OF ASIA PACIFIC: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 165 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 166 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 167 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 168 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 169 REST OF ASIA PACIFIC: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 170 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.5 LATIN AMERICA
9.5.1 RISING AWARENESS OF ADVANCED CANCER SCREENING TECHNOLOGIES TO DRIVE MARKET
TABLE 171 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 172 LATIN AMERICA: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 173 LATIN AMERICA: MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 174 LATIN AMERICA: MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 175 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 176 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 177 LATIN AMERICA: HPV TES AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 178 LATIN AMERICA: HPV TES AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 179 LATIN AMERICA: HPV TES AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 180 LATIN AMERICA: HPV TES AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)
9.6 MIDDLE EAST AND AFRICA
9.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE DUE TO HIGH CANCER BURDEN TO SUPPORT MARKET GROWTH
TABLE 181 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 182 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 183 MIDDLE EAST AND AFRICA: HPV TEST AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 184 MIDDLE EAST AND AFRICA: HPV TEST AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 185 MIDDLE EAST AND AFRICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 186 MIDDLE EAST AND AFRICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 187 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 188 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 189 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 190 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 148)
10.1 OVERVIEW
10.2 STRATEGIES ADOPTED BY KEY PLAYERS
10.2.1 HPV TESTING AND PAP TEST MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 191 OVERVIEW OF STRATEGIES ADOPTED BY KEY HPV TESTING AND PAP TEST PLAYERS
10.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
FIGURE 26 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
10.4 MARKET SHARE ANALYSIS
FIGURE 27 GLOBAL MARKET SHARE, BY KEY PLAYER (2021)
TABLE 192 GLOBAL MARKET: DEGREE OF COMPETITION
10.5 COMPANY EVALUATION QUADRANT
10.5.1 LIST OF EVALUATED VENDORS
10.5.2 STARS
10.5.3 EMERGING LEADERS
10.5.4 PERVASIVE PLAYERS
10.5.5 PARTICIPANTS
FIGURE 28 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 29 MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
10.7 COMPETITIVE SCENARIO
10.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 193 PRODUCT LAUNCHES & APPROVALS (2020-2022)
10.7.2 DEALS
TABLE 194 DEALS (2021-2022)
10.7.3 OTHER DEVELOPMENTS
TABLE 195 OTHER DEVELOPMENTS
11 COMPANY PROFILES (Page No. - 158)
11.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 ABBOTT LABORATORIES
TABLE 196 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 30 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
11.1.2 ROCHE DIAGNOSTICS
TABLE 197 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 31 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021)
11.1.3 HOLOGIC, INC.
TABLE 198 HOLOGIC, INC.: BUSINESS OVERVIEW
FIGURE 32 HOLOGIC, INC: COMPANY SNAPSHOT (2021)
11.1.4 BECTON, DICKINSON AND COMPANY
TABLE 199 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
11.1.5 QUEST DIAGNOSTICS
TABLE 200 QUEST DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 34 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2021)
11.1.6 QIAGEN N.V.
TABLE 201 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
11.1.7 SEEGENE, INC.
TABLE 202 SEEGENE, INC: BUSINESS OVERVIEW
11.1.8 FEMASYS, INC.
TABLE 203 FEMASYS, INC.: BUSINESS OVERVIEW
11.1.9 ARBOR VITA CORPORATION
TABLE 204 ARBOR VITA CORPORATION: BUSINESS OVERVIEW
11.1.10 MYLAB DISCOVERY SOLUTIONS PVT. LTD.
TABLE 205 MYLAB DISCOVERY SOLUTIONS PVT. LTD.: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS
11.2.1 EVERLYWELL INC.
TABLE 206 EVERLYWELL INC.: COMPANY OVERVIEW
11.2.2 NURX INC.
TABLE 207 NURX INC.: COMPANY OVERVIEW
11.2.3 DALRADA CORPORATION
TABLE 208 DALRADA CORPORATION: COMPANY OVERVIEW
11.2.4 NEODIAGNOSTIX
TABLE 209 NEODIAGNOSTIX: COMPANY OVERVIEW
11.2.5 JIANGSU MOLE BIOSCIENCE CO., LTD.
TABLE 210 JIANGSU MOLE BIOSCIENCE CO., LTD.: COMPANY OVERVIEW
11.2.6 SANSURE BIOTECH INC.
TABLE 211 SANSURE BIOTECH, INC.: COMPANY OVERVIEW
12 APPENDIX (Page No. - 183)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the HPV testing and Pap test market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the global market size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the HPV testing and Pap test market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global HPV testing and Pap test Market Size: Top-Down Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the HPV testing and Pap test market by test type, end user and region.
- To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities and challenges).
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa,
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
- To track and analyze company developments such as product launch, product approval, expansion, acquisition, collaboration in the global market.
- To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product strategy.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- HPV testing and Pap test market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa.
Company profiles
- Product portfolio matrix for leading market players.
Generating Response ...
Growth opportunities and latent adjacency in HPV Testing and Pap Test Market